Search Results - "Park, Daniel Youngjae"
-
1
The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system
Published in Nature communications (16-02-2022)“…Targeted protein degradation allows targeting undruggable proteins for therapeutic applications as well as eliminating proteins of interest for research…”
Get full text
Journal Article -
2
Targeted degradation of ⍺-synuclein aggregates in Parkinson's disease using the AUTOTAC technology
Published in Molecular neurodegeneration (24-06-2023)“…There are currently no disease-modifying therapeutics for Parkinson's disease (PD). Although extensive efforts were undertaken to develop therapeutic…”
Get full text
Journal Article -
3
Author Correction: The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system
Published in Nature communications (12-04-2022)Get full text
Journal Article -
4
Correction: Targeted degradation of ⍺-synuclein aggregates in Parkinson’s disease using the AUTOTAC technology
Published in Molecular neurodegeneration (29-09-2023)Get full text
Journal Article -
5
Targeted protein degradation via the autophagy-lysosome system: AUTOTAC (AUTOphagy-TArgeting Chimera)
Published in Autophagy (02-09-2022)“…Targeted protein degradation allows targeting undruggable proteins for therapeutic applications as well as eliminating proteins of interest for research…”
Get full text
Journal Article -
6
Regulation of reticulophagy by the N-degron pathway
Published in Autophagy (01-02-2020)“…Cellular homeostasis requires selective autophagic degradation of damaged or defective organelles, including the endoplasmic reticulum (ER). Previous studies…”
Get full text
Journal Article -
7
Correction: Targeted degradation of âº-synuclein aggregates in Parkinson's disease using the AUTOTAC technology
Published in Molecular neurodegeneration (29-09-2023)Get full text
Journal Article -
8
Targeted degradation of âº-synuclein aggregates in Parkinson's disease using the AUTOTAC technology
Published in Molecular neurodegeneration (24-06-2023)“…Background There are currently no disease-modifying therapeutics for Parkinson's disease (PD). Although extensive efforts were undertaken to develop…”
Get full text
Journal Article